Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,668Revenue $M22.0Net Margin (%)-399.9Altman Z-Score46.3
Enterprise Value $M3,291EPS $-1.0Operating Margin %-424.5Piotroski F-Score5
P/E(ttm)--Beneish M-Score20.5Pre-tax Margin (%)-399.9Higher ROA y-yY
Price/Book6.910-y EBITDA Growth Rate %--Quick Ratio19.3Cash flow > EarningsY
Price/Sales1445-y EBITDA Growth Rate %--Current Ratio19.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-19.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-21.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M86.2ROIC % (ttm)-127.7Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 35.99161%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 35.99193%New holding200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 35.99374%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 35.99401%Add 23.80%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 35.99401%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 35.99353%New holding209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 35.99353%New holding150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 35.99432%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 35.99436%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 35.99377%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 35.99400%Add 23.00%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 35.99372%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OBrien Christopher FlintChief Medical Officer 2016-02-03Sell1,500$38.01-5.31view
Grigoriadis Dimitri E.Chief Research Officer 2016-02-03Sell1,375$37.98-5.24view
GORMAN KEVIN CHARLESPresident and CEO 2016-02-03Sell3,125$38.04-5.39view
Gano KyleChief Business Development Off 2016-02-03Sell1,375$37.98-5.24view
Coughlin Timothy PCFO 2016-02-03Sell1,500$38.06-5.44view
Bozigian Haig P.Chief Development Officer 2016-02-03Sell1,375$38.13-5.61view
OBrien Christopher FlintChief Medical Officer 2016-01-19Sell1,750$46.77-23.05view
Grigoriadis Dimitri E.Chief Research Officer 2016-01-19Sell1,625$46.76-23.03view
GORMAN KEVIN CHARLESPresident and CEO 2016-01-19Sell3,750$46.7-22.93view
Gano KyleChief Business Development Off 2016-01-19Sell1,625$46.84-23.16view

Quarterly/Annual Reports about NBIX:

    News about NBIX:

    Articles On GuruFocus.com
    Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
    Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
    Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
    5 Strong Healthcare Stocks For 2012 Mar 24 2012 
    Consider These 5 Healthcare Stocks Now Mar 21 2012 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 

    More From Other Websites
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 05 2016
    Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 03 2016
    Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in... Feb 02 2016
    Stock Watchout on Drugs - Generic -- Mylan, Neurocrine Biosciences, Horizon Pharma, and Zoetis Feb 02 2016
    AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine... Jan 28 2016
    Four Stocks Driving Thursday’s Market Gains: How Did They Do It? Jan 14 2016
    Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 5, 2016 Jan 05 2016
    Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : January 5,... Jan 05 2016
    Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
    Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
    4 stocks to watch Dec 31 2015
    5 Top Performing Stocks of the Top ETF of 2015 Dec 28 2015
    Niche Hedge Funds lead the pack in 2015 Dec 22 2015
    Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : December 22,... Dec 22 2015
    NBIX: Successful Phase 1b Trial Results for NBI-98854 in Tourette Syndrome Caps a Banner Year for... Dec 18 2015
    Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in... Dec 16 2015
    NEUROCRINE BIOSCIENCES INC Financials Dec 08 2015
    Icahn School Of Medicine At Mount Sanai Files Complaint Against Neurocrine Sciences For Breach Of... Dec 02 2015
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events Dec 02 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK